JP2022522405A5 - - Google Patents
Info
- Publication number
- JP2022522405A5 JP2022522405A5 JP2021543386A JP2021543386A JP2022522405A5 JP 2022522405 A5 JP2022522405 A5 JP 2022522405A5 JP 2021543386 A JP2021543386 A JP 2021543386A JP 2021543386 A JP2021543386 A JP 2021543386A JP 2022522405 A5 JP2022522405 A5 JP 2022522405A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- amino acid
- acid sequence
- mhc class
- sequence identity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962814721P | 2019-03-06 | 2019-03-06 | |
| US62/814,721 | 2019-03-06 | ||
| PCT/US2020/021138 WO2020181062A1 (en) | 2019-03-06 | 2020-03-05 | T-cell modulatory multimeric polypeptides and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022522405A JP2022522405A (ja) | 2022-04-19 |
| JP2022522405A5 true JP2022522405A5 (cg-RX-API-DMAC7.html) | 2023-03-09 |
Family
ID=72338760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021543386A Pending JP2022522405A (ja) | 2019-03-06 | 2020-03-05 | T細胞調節多量体ポリペプチド及びその使用方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US20220105162A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3935080A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022522405A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020181062A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110325205B (zh) | 2016-12-22 | 2023-08-15 | 库尔生物制药有限公司 | T细胞调节性多聚体多肽及其使用方法 |
| KR20240005989A (ko) | 2017-03-15 | 2024-01-12 | 큐 바이오파마, 인크. | 면역 반응을 조절하는 방법 |
| CA3061614A1 (en) | 2017-04-28 | 2018-11-01 | The Regents Of The University Of Colorado, A Body Corporate | Methods of treating rheumatoid arthritis using rna-guided genome editing of hla gene |
| WO2019051127A1 (en) | 2017-09-07 | 2019-03-14 | Cue Biopharma, Inc. | MULTIMER MODULATOR POLYPEPTIDE OF LYMPHOCYTE T HAVING CONJUGATION SITES AND METHODS OF USE THEREOF |
| IL296209A (en) | 2020-05-12 | 2022-11-01 | Cue Biopharma Inc | Multimeric t-cell modulatory polypeptides and methods of using them |
| AU2022215119A1 (en) * | 2021-01-29 | 2023-08-17 | Bayer Animal Health Gmbh | Vaccine composition for breaking self-tolerance |
| JP2024517658A (ja) * | 2021-04-21 | 2024-04-23 | キュー バイオファーマ, インコーポレイテッド | 1型真性糖尿病(t1d)を治療するためのmhcクラスii t細胞調節ポリペプチド及びその使用方法 |
| WO2022226037A1 (en) * | 2021-04-21 | 2022-10-27 | Cue Biopharma, Inc. | Antigen presenting polypeptide complexes bearing tgf-beta and methods of use thereof |
| WO2022226073A1 (en) * | 2021-04-21 | 2022-10-27 | Cue Biopharma, Inc. | Mhc class ii t-cell modulatory polypeptides and methods of use thereof |
| MX2023013438A (es) | 2021-05-10 | 2024-02-29 | Univ Colorado Regents | Métodos de diseño de hla y composiciones para el tratamiento de la autoinmunidad. |
| US20240327492A1 (en) * | 2021-07-29 | 2024-10-03 | Nantcell, Inc. | Modified T Cell Receptors For The Prevention And Treatment Of Viral Infections And Cancer |
| WO2025111562A1 (en) * | 2023-11-22 | 2025-05-30 | Cue Biopharma, Inc. | Mhc class ii protein complexes |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| ATE237694T1 (de) | 1991-08-20 | 2003-05-15 | Us Gov Health & Human Serv | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| EP0673431A1 (en) | 1992-12-03 | 1995-09-27 | Genzyme Corporation | Gene therapy for cystic fibrosis |
| EP0705344B8 (en) | 1993-06-24 | 2006-05-10 | Advec Inc. | Adenovirus vectors for gene therapy |
| DE69435223D1 (de) | 1993-10-25 | 2009-09-03 | Canji Inc | Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung |
| DK0776339T4 (da) * | 1994-07-29 | 2010-05-25 | Sunol Molecular Corp | MHC-komplekser og anvendelser deraf |
| US7078387B1 (en) | 1998-12-28 | 2006-07-18 | Arch Development Corp. | Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors |
| US6287860B1 (en) | 2000-01-20 | 2001-09-11 | Isis Pharmaceuticals, Inc. | Antisense inhibition of MEKK2 expression |
| JP2005522192A (ja) | 2001-07-19 | 2005-07-28 | パーラン セラピューティクス, インコーポレイテッド | マルチマータンパク質およびマルチマータンパク質を作製および使用する方法 |
| US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
| CA2644712C (en) | 2006-03-06 | 2016-09-13 | Amunix, Inc. | Unstructured recombinant polymers and uses thereof |
| CA2695374A1 (en) | 2007-08-15 | 2009-02-19 | Amunix, Inc. | Compositions and methods for modifying properties of biologically active polypeptides |
| DK3178835T3 (da) | 2009-02-03 | 2019-06-24 | Amunix Pharmaceuticals Inc | Forlængede rekombinante polypeptider og sammensætninger omfattende samme |
| EP2593551B1 (en) * | 2010-07-15 | 2016-09-14 | Technion Research & Development Foundation Ltd. | Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and glutamic acid decarboxylase (gad) autoantigenic peptides |
| JP6652932B2 (ja) * | 2014-06-18 | 2020-02-26 | アルバート アインシュタイン カレッジ オブ メディシン | synTacポリペプチド及びその使用 |
| ES3055030T3 (en) * | 2015-05-06 | 2026-02-09 | Uti Lp | Nanoparticle compositions for sustained therapy |
| IL262606B2 (en) * | 2016-05-18 | 2023-04-01 | Albert Einstein College Medicine Inc | pd-l1 variant polypeptides, T-cell modulatory multimeric polypeptides, and methods of using them |
| US20180127481A1 (en) * | 2016-11-09 | 2018-05-10 | Uti Limited Partnership | RECOMBINANT pMHC CLASS II MOLECULES |
| CN110325205B (zh) * | 2016-12-22 | 2023-08-15 | 库尔生物制药有限公司 | T细胞调节性多聚体多肽及其使用方法 |
| KR20240005989A (ko) * | 2017-03-15 | 2024-01-12 | 큐 바이오파마, 인크. | 면역 반응을 조절하는 방법 |
-
2020
- 2020-03-05 WO PCT/US2020/021138 patent/WO2020181062A1/en not_active Ceased
- 2020-03-05 EP EP20765925.1A patent/EP3935080A4/en not_active Withdrawn
- 2020-03-05 JP JP2021543386A patent/JP2022522405A/ja active Pending
-
2021
- 2021-08-05 US US17/394,972 patent/US20220105162A1/en not_active Abandoned
-
2025
- 2025-02-14 US US19/054,201 patent/US20250242005A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022522404A5 (cg-RX-API-DMAC7.html) | ||
| JP2021500855A5 (cg-RX-API-DMAC7.html) | ||
| Todd et al. | A molecular basis for genetic susceptibility to insulin-dependent diabetes mellitus | |
| Choo | The HLA system: genetics, immunology, clinical testing, and clinical implications | |
| Todd et al. | A molecular basis for MHC class II—associated autoimmunity | |
| Kelly et al. | A new human HLA class II-related locus, DM | |
| Spies et al. | Presentation of viral antigen by MHC class I molecules is dependent on a putative peptide transporter heterodimer | |
| Flajnik et al. | Evolution of the major histocompatibility complex: molecular cloning of major histocompatibility complex class I from the amphibian Xenopus. | |
| AU2025202532A9 (en) | HLA Class II-restricted T cell receptors against mutated RAS | |
| Czaja | Genetic factors affecting the occurrence, clinical phenotype, and outcome of autoimmune hepatitis | |
| JP2022536581A5 (cg-RX-API-DMAC7.html) | ||
| JP2022534846A5 (cg-RX-API-DMAC7.html) | ||
| JP2022515330A5 (cg-RX-API-DMAC7.html) | ||
| JP2019512222A5 (cg-RX-API-DMAC7.html) | ||
| Gregersen | HLA class II polymorphism: implications for genetic susceptibility to autoimmune disease | |
| JP2023541366A5 (cg-RX-API-DMAC7.html) | ||
| Parham et al. | HLA-A, B, C: Patterns of polymorphism in peptide-binding proteins | |
| Thorsby et al. | Role of HLA genes in predisposition to develop insulin-dependent diabetes mellitus | |
| Cook et al. | Structural Studies on the Murine Ia Alloantigens: IV. NH2-Terminal Sequence Analysis of Allelic Products of the IA and IE/C Subregions | |
| EP0286447B1 (en) | Method and agents relating to prophylactic treatment of autoimmune diseases | |
| Hurley et al. | Polymorphism of the HLA-DR1 haplotype in American blacks. Identification of a DR1 beta-chain determinant recognized in the mixed lymphocyte reaction. | |
| Ababou et al. | Evidence for the expression of three different BoLA-class II molecules on the bovine BL-3 cell line: determination of a non-DR non-DQ gene product | |
| Nepom | MHC genes in HLA-associated disease | |
| Weyand et al. | Mapping of allospecific T-cell recognition sites encoded by the HLA-DR4 β1-chain | |
| Deschamps et al. | The role of genetic predisposition to type I (insulin-dependent) diabetes mellitus |